Fannie Mae, Freddie Mac shares tumble after conservatorship comments
PLEASANTON, Calif. - Boehringer Ingelheim has standardized its customer data across more than 100 countries using Veeva OpenData and Veeva Network, becoming the latest top 20 pharmaceutical company to adopt these solutions, according to a press release issued Wednesday. Veeva (NYSE:VEEV), which maintains an excellent financial health score according to InvestingPro analysis, has been delivering consistent revenue growth of nearly 15% over the last twelve months.
The implementation aims to provide Boehringer Ingelheim’s teams with accurate customer reference data to engage healthcare professionals more effectively while establishing a foundation for scaling artificial intelligence capabilities. With a robust gross margin of 75.5% and strong liquidity position, Veeva continues to invest in its product development and customer solutions.
"Extending our trusted partnership with Veeva by adopting globally harmonized data will strengthen customer engagement and pave the way for future AI use cases," said Uday Bose, head of human pharma global customer experience excellence and business steering at Boehringer Ingelheim.
By consolidating its data strategy into a single comprehensive solution, the pharmaceutical company expects to simplify data management and improve efficiencies. The standardization is designed to ensure consistent, high-quality customer data across teams and regions, while enhancing cross-team collaboration.
The connected software and data from Veeva (NYSE:VEEV) will also streamline Boehringer Ingelheim’s migration to Veeva Vault CRM through native integrations with OpenData and Network.
Veeva OpenData is part of Veeva Data Cloud, which includes several other Veeva products. Veeva Network is included in the Vault CRM Suite that connects sales, marketing, and medical teams.
The announcement represents an expansion of the existing relationship between the two companies, with the data solutions expected to provide a unified customer view across Boehringer Ingelheim’s global operations. For investors seeking deeper insights into Veeva’s performance and potential, InvestingPro offers comprehensive analysis with 14+ additional ProTips and detailed financial metrics in its Pro Research Report.
In other recent news, Veeva Systems announced its fiscal first-quarter 2026 results, showcasing strong performance driven by its Crossix Solution. Analysts from Mizuho and Jefferies responded positively, raising their price targets to $295 and $335, respectively, while maintaining favorable ratings. Veeva Systems also secured a new commitment from Merck, marking the sixth top 20 global pharmaceutical company to adopt its Vault platform. Additionally, Astellas has chosen Veeva Vault CRM for its global operations, including a specialized version for China, emphasizing the importance of commercial agility. In another development, the Sarah Cannon Research Institute (SCRI) entered into a strategic collaboration with Veeva Systems to adopt the Veeva Clinical Platform. This partnership aims to enhance the delivery of oncology clinical trials across SCRI’s extensive network. These recent developments highlight Veeva Systems’ growing influence and adoption in the life sciences industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.